VA/DoD Obesity Guideline Update Backs Personalized, Long-Term Care

What Was Updated

The U.S. Department of Veterans Affairs and Department of Defense (VA/DoD) updated their obesity management guideline in 2025 to reflect advances in obesity assessment and treatments.

A synopsis of the updated guideline, aimed at primary care physicians, was published in Annals of Internal Medicine in 2026.

• The guideline emphasizes assessing health risks beyond body mass index (BMI) alone.
• It describes comprehensive lifestyle intervention as the foundation of care.
• It supports flexible integration of medications, including GLP-1 therapies, and endoscopic and surgical options when appropriate.

What The Evidence Review Covered

The VA/DoD Evidence-Based Practice Work Group convened a multidisciplinary panel of clinical stakeholders to review the evidence and practical considerations for obesity management.

The panel reviewed evidence published from April 1, 2019, through Jan. 6, 2025, and evaluated benefits, risks, patient preferences, and practical considerations.

• The synopsis reports the work as an evidence review informing a clinical practice guideline update.
• The source does not report new trial results or effect sizes in the synopsis.

What The Guideline Recommends In Primary Care

The guideline recommends routine obesity screening using BMI alongside waist circumference and clinical context, rather than relying on BMI alone.

It supports comprehensive lifestyle intervention as the cornerstone of care and encourages timely, individualized use of medications and endoscopic and surgical procedures when needed.

• Screen with BMI plus waist circumference and clinical context.
• Start with comprehensive lifestyle intervention as baseline treatment.
• Add medications, including GLP-1 therapies, when appropriate for the individual patient.
• Consider endoscopic or surgical options when needed, based on clinical context.

Why This Matters For Metabolic Health

The authors conclude that obesity should be treated as a chronic disease requiring longitudinal, flexible care pathways.

In practice, the guideline’s framing connects obesity care to ongoing monitoring and treatment adjustments over time, rather than a single short-term weight-loss plan.

• The update centers “health risks beyond BMI,” which can affect how metabolic risk is discussed and tracked.
• The guideline positions medications and procedures as add-ons to lifestyle care when needed, rather than as stand-alone steps.

Limitations And What The Synopsis Does Not Say

The MedicalXpress article is a synopsis-style report of a VA/DoD guideline update and does not provide medication-specific criteria, dosing, or effect sizes in the text provided.

The source also does not specify which patient groups are eligible for particular medications or procedures, beyond stating that use should be timely and individualized and guided by clinical context.

• No GLP-1 drug names, doses, or prescribing thresholds are provided in the supplied text.
• The synopsis describes the evidence review window and recommendations, but not detailed outcomes by intervention.